EP0262212A1 - Biotinylated psoralens - Google Patents

Biotinylated psoralens

Info

Publication number
EP0262212A1
EP0262212A1 EP19870903009 EP87903009A EP0262212A1 EP 0262212 A1 EP0262212 A1 EP 0262212A1 EP 19870903009 EP19870903009 EP 19870903009 EP 87903009 A EP87903009 A EP 87903009A EP 0262212 A1 EP0262212 A1 EP 0262212A1
Authority
EP
European Patent Office
Prior art keywords
psoralen
nucleic acid
biotinylated
avidin
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870903009
Other languages
German (de)
French (fr)
Inventor
Wilma A. Saffran
Richard L. Edelson
Francis P. Gasparro
John T. Welsh
Charles R. Cantor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University of New York
Original Assignee
Columbia University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University of New York filed Critical Columbia University of New York
Publication of EP0262212A1 publication Critical patent/EP0262212A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Definitions

  • Psoralen is a linear three ring heterocyclic compound having the structure
  • Psoralen's ability to react with DNA has given it clinical importance in the treatment of psoriasis and other skin disorders. Additionally, its ability to form interstrand crosslinks in double stranded DNA has made it a useful reagent in the study of nucleic acid structure and function.
  • Biotin a growth factor present in very minute amounts in every living cell and occurring mainly bound to proteins or polypeptides, has the structure
  • Avidin is a glycoprotein containing four essentially identical subunits, each of which is a single polypeptide chain of 128 amino acid residues with a carbohydrate moiety attached at position 17 (3).
  • Biotin combines with avidin and becomes inactive (4 , 5) .
  • antigens are recognized by specif ic antibodies, which are then bound to a biotinylated anti-immunoglobul in. This then forms a tight complex with avidin, either conj ugated directly to a signal of some kind, such as a fluorescent dye or enzyme, or in turn bound to a biotinylated label.
  • molecules that are themselves di rectly biotinylated can be recognized di rectly by avidin, omitting the antibody reactions, with their somewhat lower affinities.
  • Cimino et al. (6) described the synthesis of a psoralen derivative (aminomethyltrioxsalen-AMT) which contains a biotin moiety attached to the 4' position by various undisclosed linker chains. However, the purported methods for synthesizing these compounds were not disclosed. Furthermore, Cimino et al. reported only that preliminary studies of these undisclosed compunds indicated that they could be used to interchalate and crosslink double-stranded nucleic acid and that they can be detected colorimetrically or fluorescently by standard methods based on the avidinbiotin interaction.
  • biotinylated psoralens which retain the biological activity of psoralen and the binding specificity of biotin for avidin are not known. Furthermore, methods for synthesizing compounds which retain the biological activity of psoralen and the binding specificity of biotin are not known.
  • a quick, easy, efficient, and safe method for preparing a biotinylated psoralen would provide readily accessible amounts of biotinylated psoralens useful for psoralen modification of cellular components, the visualization of minute amounts of DNA, investigations of the uptake and distribution of psoralen within cells, the delivery of psoralen to specific cells, and the conversion of nucleic acid molecules to ligands for avidin.
  • the present invention provides a compound having the formula
  • Y is biotin or iminobiotin
  • X is CH 2
  • P is psoralen or a psoralen derivative
  • r is an integer equal to or greater than 2
  • s is an integer equal to or greater than 1.
  • the invention also provides a method for preparing a biotinylated psoralen derivative which comprises treating a compound having the structure
  • a positively charge multi-aminated linker having two amine groups separated by at least two carbon atoms under suitable conditions so as to allow the formation of a psoralen-linker complex.
  • the psoralen-linker complex is treated with the N-hydroxy succinimide ester of either biotin or iminobiotin under suitable conditions so as to allow the formation of a psoralen-linker-biotin or -iminobiotin complex.
  • This method comprises binding a suitable carrier molecule to biotin so as to form a biotinylated carrier.
  • the biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then reversibly bound to an iminobiotinylated psoralen so as to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex.
  • Cells are treated with a suitable amount of the iminobiotinylated psoralen-avidin-biotinylated carrier complex under suitable conditions so as to permit the iminobiotinylated psoralen-avidin-biotinylated carrier complex to become internalized.
  • the treated cells are incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into a nucleic acid.
  • the incubated cells are then irradiated with near ultraviolet light under suitable conditions to allow the intercalated iminobiotinylated psoralen to covalently bind to the nucleic acid into which it has intercalated, thereby delivering to the cell an iminobiotinylated psoralen.
  • the invention further provides a method for treating leukemia in a subject.
  • This method comprises binding a suitable carrier molecule to biotin to form a biotinylated carrier.
  • the biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then bound to an iminobiotinylated psoralen to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex.
  • Separetely, plasma and red blood cells are separated from a sample of blood cells and a leukocyte enriched composition is recovered.
  • This leukocyte enriched composition is treated with a suitable amount of the iminobiotinylated psoralen avidin-biotinylated carrier complex, which is permitted to become internalized.
  • the treated leukocyte enriched composition is incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into DNA within the cells.
  • the incubated, treated leukocyte enriched composition is then irradiated with near ultraviolet light so as to allow the intercalated iminobiotinylated psoralen moiety to covalently bind to the DNA into which is has intercalated.
  • a suitable amount of the irradiated leukocyte enriched composition is then administered to the subject, thereby treating the subject for leukemia by providing a toxic dose of psoralen to the leukemic DNA of the subject.
  • the invention additionally provides a method for detecting the presence of a nucleic acid in a sample.
  • This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid.
  • the sample is then irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which is has intercalated.
  • the biotinylated psoralen which is covalently bound to the nucleic acid is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid.
  • the presence of avidin bound to the biotinylated psoralen, which is also covalenty bound to the nucleic acid is detected and thereby the presence of the nucleic acid in the sample is detected.
  • the amount of a nucleic acid in a sample may be quantitatively determined by contacting the biotinylated psoralen which is covalently bound to the nucleic acid with a known amount of a detectably marked avidin. By determining the amount of avidin bound to the biotinylated psoralen which is also covalently bound to the nucleic acid, the amount of the nucleic acid in the sample is also determined.
  • the invention also provides a method for purifying or isolating nucleic acid from a sample.
  • This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid.
  • the sample is irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated.
  • the biotinylated psoralen which is covalently bound to the nucleic acid, is then contacted with an immobilized avidin under suitable condi ti ons so as to allow the avidin moiety to bind to the biotinylated psoralen and form an avidin-biotinylated psoralen-nucleic acid complex.
  • the nucleic acid may then be recovered from the avidin-biotinylated psoralen-nucleic acid complex.
  • the invention provides a method for total nucleic acid pattern visualization of a sample.
  • This method comprises electrophoresing the nucleic acid of the sample and immobilizing it to a solid support.
  • the immobilized nucleic acid is contacted with a biotinylated psoralen and the solid support is incubated in the dark for an appropriate amount of time so as to allow the biotinylated psoralen to intercalate into a nucleic acid.
  • Non-intercalated biotinylated psoralen is removed from the solid support and nucleic acid complexes bound to the solid support and intercalated with biotinylated psoralen are irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated.
  • the solid support is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind the biotinylated psoralen, which is covalently bound to the nucleic acid.
  • the presence of avidin bound to the biotinylated psoralen is detected and thereby the total nucleic acid pattern of the sample is visualized.
  • the invention provides a method for visualizing a specific nucleic acid in a sample.
  • This method comprises electrophoresing the nucleic acid of the sample and immobilizing the electrophoresed nucleic acid to a solid support.
  • the immobilized nucleic acid is denatured so as to produced single stranded nucleic acids.
  • a single stranded nucleic acid clone of the specific nucleic acid to be visualized is contacted with a biotinylated psoralen.
  • the nucleic acid clone is incubated under suitable conditions in the dark so as to allow the formation of biotinylated psoralen-nucleic acid clone complexes, which are then irradiated with near ultraviolet light so as to permit the biotinylated psoralen to covalently bind the nucleic acid clone into which it has intercalated.
  • the immobilized single stranded nucleic acids are contacted with the nucleic acid clone which is covalently bound to the biotinylated psoralen so as to allow the nucleic acid clone and the immobilized single stranded nucleic acids to hybridize.
  • Fig. 1 Synthesis of biotinylated psoralen.
  • Fig. 2 DNA crossl inking by BPsor.
  • Linear pBR322 DNA (0.2 micrograms) was near UV irradiated in the presence BPsor.
  • Lane 1 no psoralen
  • lane 2 6 ng
  • lane 3 15 ng
  • lane 4 30 ng
  • lane 5 30 ng psoralen, but no irradiation.
  • Fig. 3 Detection of BPsor modification of DNA by ELISA. Modified DNA on microtiter dishes was incubated sequentially with streptavidin, biotinylated poly alkaline phosphatase, and phosphatase substrate.
  • Fig. 4 ELISA of BPsor modified DNA. Alkaline phosphatase activity in samples of DNA reacted with BPsor + near UV light ( ⁇ ) or BPsor alone, without irradiation ( ⁇ ).
  • the present invention pr ovi des a compound having th e f ormul a
  • Y is biotin or iminobiotin
  • X is CH 2
  • P is psoralen or a psoralen derivative
  • r is an integer equal to or greater than 2
  • s is an integer equal to or greater than 1.
  • X is bound to the 4' position of psoralen or a psoralen derivative.
  • the psoralen derivative may be 4, 5', 8 - trimethylpsoralen or 8 - methoxypsoralen.
  • r is the integer 2 and s is the integer 1.
  • the invention also provides a method for preparing a biotinylated psoralen or a biotinylated psoralen derivative which comprises treating a compound having the structure
  • L is chlorine, bromine, or iodine and P is psoralen or a psoralen derivative linked to L by CH 2 at the 4' position of P with a positively charge multi-ami nated linker having two amine groups separated by at least two carbon atoms under suitable conditions so as to allow the formation of a psoralen-linker complex.
  • the psoralen-linker complex is treated with the N-hydroxy succinimide ester of either biotin or iminobiotin under suitable conditions so as to allow the formation of a psoralen-linker-biotin or -iminobiotin complex.
  • This method comprises binding a suitable carrier molecule, i.e. a molecule which is capable of cellular internalization by receptor mediated endocytosis, to biotin so as to form a biotinylated carrier.
  • the biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then reversibly bound to an iminobiotinylated psoralen so as to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex.
  • Cells are treated with a suitable amount of the iminobiotinylated psoralen-avidin-biotinylated carrier complex under suitable conditions so as to permit the iminobiotinylated psoralen-avidin-biotinylated carrier complex to become internalized.
  • the treated cells are incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into a nucleic acid.
  • suitable carrier molecule includes, but is not limited to, insulin and transferrin.
  • the invention further provides a method for treating leukemia in a subject.
  • This method comprises binding a suitable carrier molecule to biotin to form a biotinylated carrier.
  • the biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then bound to an iminobiotinylated psoralen to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex.
  • a leukocyte enriched composition is recovered.
  • This leukocyte enriched composition is treated with a suitable amount of the iminobiotinylated psoralen avidin-biotinylated carrier complex, which is permitted to become internalized.
  • the treated leukocyte enriched composition is incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into DNA within the cells.
  • the invention additionally provides a method for detecting the presence of a nucleic acid in a sample.
  • This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid.
  • the sample is then irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which is has intercalated.
  • the biotinylated psoralen which is covalently bound to the nucleic acid is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid.
  • the presence of avidin bound to the biotinylated psoralen, which is also covalenty bound to the nucleic acid is detected and thereby the presence of the nucleic acid in the sample is detected.
  • the invention also provides a method for purifying or isolating nucleic acid from a sample.
  • This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid.
  • the sample is irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated.
  • the biotinylated psoralen which is covalently bound to the nucleic acid, is then contacted with an immobilized avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen and form an avidin-biotinylated psoralen-nucleic acid complex.
  • the nucleic acid may then be recovered from the avidin-biotinylated psoralen-nucleic acid complex.
  • the invention provides a method for total nucleic acid pattern visualization of a sample.
  • This method comprises electrophoresing the nucleic acid of the sample and immobilizing it to a solid support.
  • the immobilized nucleic acid is contacted with a biotinylated psoralen and the solid support is incubated in the dark for an appropriate amount of time so as to allow the biotinylated psoralen to intercalate into a nucleic acid.
  • Non-intercalated biotinylated psoralen is removed from the solid support and nucleic acid complexes bound to the solid support and intercalated with biotinylated psoralen are irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated.
  • the solid support is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind the biotinylated psoralen, which is covalently bound to the nucleic acid.
  • the presence of avidin bound to the biotinylated psoralen is detected and thereby the total nucleic acid pattern of the sample is visualized.
  • the invention provides a method for visualizing a specific nucleic acid in a sample.
  • This method comprises electrophoresing the nucleic acid of the sample and immobilizing the electrophoresed nucleic acid to a solid support.
  • the immobilized nucleic acid is denatured so as to produced single stranded nucleic acids.
  • a single stranded nucleic acid clone of the specific nucleic acid to be visualized is contacted with a biotinylated psoralen.
  • the nucleic acid clone is incubated under suitable conditions in the dark so as to allow the formation of biotinylated psoralen-nucleic acid clone complexes, which are then irradiated with near ultraviolet light so as to permit the biotinylated psoralen to covalently bind the nucleic acid clone into which it has intercalated.
  • the immobilized single stranded nucleic acids are contacted with the nucleic acid clone which is covalently bound to the biotinylated psoralen so as to allow the nucleic acid clone and the immobilized single stranded nucleic acids to hybridize.
  • the invention also provides a cross-linked double stranded nucleic acid represented by the structure wherein A is a purine or a pyrimidine, B 2 and B 3 are purines, B 1 and B 4 are pyrimdines, W is a biotinylated psoralen cross-linked to B 1 and B 4 such that the 3, 4 and 4', 5' double bonds of W react with the 5, 6 double bonds of B 1 and B 4 to form cyclobutane products, Z is H or OH and m and n are integers from 0 to about 100,000.
  • A is a purine or a pyrimidine
  • B is a pyrimidine
  • W is a biotinylated psoralen linked to B such that either the 3, 4 or the 4', 5' double bond of W reacts with the 5, 6 double bond of B to form a cyclobutane product
  • Z is H or OH
  • m and n are integers from 0 to 100,000.
  • the invention further provides a method for detecting in a sample a biotinylated substance.
  • This method comprises contacting a cross-linked double stranded nucleic acid of the present invention with avidin under suitable conditions to allow the avidin to bind to the biotinylated psoralen moiety and form an avidin-biotinylated psoralen-nucleic acid complex.
  • the sample is contacted with the avidin-biotinylated psoralen-nucleic acid complex under suitable conditions to allow the formation of a biotinylated substance-avidin-biotinylated psoralen-nucleic acid complex, the nucleic acid moiety of which is detected, thereby detecting the presence of the biotinylated substances.
  • the biotinylated substance which is detected may be a biotinylated molecule, cell component, or intact cell.
  • nucleic acid moiety may be detected by a colorimetric, chemical, or radioactive technique.
  • a method for detecting in a sample an avidinylated substance is also provided by the present invention.
  • This method comprises contacting the sample with a cross-linked double stranded nucleic acid molecule of the present invention under suitable conditions to allow the formation of avidinylated substance-biotinylated psoralen-nucleic acid complexes. The presence of the nucleic acid moiety of the complexes is detected, thereby detecting the presence of the avidinylated substance.
  • the avidinylated substance may be an avidinylated molecule, cell component, or intact cell. Additionally, the nucleic acid moiety may be detected by a colorimeteric, chemical, or radioactive technique.
  • Diaminepsoralen was prepared from chloromethyl-trimethylpsoralen and sym-dimethylethylene diamine (Aldrich) as described by Welsh (7). Twelve mg of DAPS were dissolved in 0.4 ml dimethylformamide and 15 mg of NHS biotin (Pierce) was added as a solid. The reaction proceeded at room temperature. Reaction progress was followed by thin layer chromatography (TLC) on silica in CH 2 Cl 2 : NH 3 saturated methanol (15:1). The R f 's of DAPS, NHS biotin, and the reaction product were 0.25, 0 and 0.28 respectively. After one hour the reaction was complete and the solvent was rotoevaporated off, leaving a yellow oil. All steps were carried out under subdued light, and vessels were covered with aluminum foil when possible.
  • TLC thin layer chromatography
  • the product was purified by flash chromatography on a 30 x 2.5 cm column of silica gel in the TLC solvent system CH 2 Cl 2 : NH 3 saturated methanol (15:1) .
  • the reaction mixture did not dissolve directly in the running solvent, so the yellow oil was first taken up in 0.1 ml CH 3 OH, and then 1.5 ml CH 2 Cl 2 was added to the solution.
  • Fractions of about 10 ml were collected by hand and analyzed by TLC.
  • Fractions 15-22 contained the reaction product, running as a single spot with blue fluorescence at R f - 0.28.
  • Fractions 17-20 were pooled, dried down, taken up in running solvent as before, and rechromatographed.
  • [ 3 H] labelled biotinylated psoralen was prepared from diaminepsoralen and [ 3 H] NHS biotin (Amersham), and purified by preparative HPLC. The specific activity was 3.8 x 10 11 cpm/mmol.
  • Plasmid pBR322 DNA was linearized with Hindlll, and the DNA purified by phenol extraction, followed by ethanol precipitation and resuspension in 10mM Tris HCl, 1mM
  • BPsor biotinylated psoralen
  • the samples were then alkali denatured and run on a non-denaturing 1% agarose gel in the Tris acetate-EDTA, as described in (9) .
  • Calf thymus DNA at a concentration of 20 micrograms/ml (30 mM base pairs) was combined with 6 uM [ 3 H] BPsor in TE buffer. The sample was irradiated with near UV light, then phenol extracted and ethanol precipitated to remove unbound psoralen. The pellet was resuspended in phosphate buffered saline (PBS). The level of BPsor addition was 0.9%, or 1 psoralen/110 base pairs.
  • PBS phosphate buffered saline
  • the plates were washed three (3) times with IX PBS-0.5% Tween 20, and 200 microliters of 1% fetal calf serum in PBS-Tween was added to block the wells. After one hour at 37°C the solution was shaken off. 100 microliters of 5 microgram/ml streptavidin (Bethesda Research
  • Lymphocytes were isolated from 50 ml of whole blood by centrifugation on Ficoll Hypaque. They were washed twice in Roswell Park Memorial Institute (RPMI) medium, then resuspended in PBS and adjusted to 10 6 cells/ml in PBS.
  • RPMI Roswell Park Memorial Institute
  • BPsor in ethanol
  • BPsor in ethanol
  • the final ethanol concentration was 1%.
  • Negative controls contained no drug, while positive controls contained 10 ng/ml AMT, in ethanol.
  • 200 microliters of the cell suspension was added to wells in microtiter plates. Two dishes were prepared, each with 10 wells of each drug concentration. One was wrapped in aluminum foil and the second was irradiated with 3 J/cm 2 of near UV light. The microtiter plates were centrituged at 1200 rpm for seven minutes, then quickly inverted to discard the PBS.
  • lymphocytes in the wells were resuspended in 100 microliters RPMI, then half the wells received 100 microliters RPMI-20% fetal calf serum, while the other half received 100 microliters RPMI-20% fetal calf serum-2% PHA.
  • the dishes were incubated for three days at 37°C.
  • Psoralens intercalate into DNA in the dark and form covalent bonds at their 3, 4 and 4', 5' double bonds with pyrimidines upon near UV irradiation. If both ends of psoralen are reacted, the result is an interstrand DNA crosslink.
  • the ability of the BPsor to form DNA crosslinks was tested by reacting linear double strand plasmid DNA with this derivative and near UV light. The DNA was then alkali denatured and loaded onto a nondenaturing agarose gel. Crosslinked DNA immediately renatures in the gel buffer and runs as the double stranded form, while non-crosslinked DNA remains single stranded and runs with greater mobility. Increasing amounts of BPsor resulted in increased levels of crosslinking after UV irradiation, while even the greatest amounts of BPsor produced no crosslinking in the absence of light ( Figure 2).
  • the measured enzyme activity was proportional to the added BPsor and after a two hour incubation, alkaline phosphatase reaction at levels two times above background were seen in the wells with 2 fmol of bound BPsor, corresponding to 0.15ng ( Figure 4). After overnight incubation, 1 fmol could be detected above background. Both BPsor and UV irradiation were required for avidin binding. The control samples, which had been incubated with BPsor but not irradiated, stayed at background levels of alkaline phosphatase activity, as did DNA which had been exposed to light in the absence of BPsor.
  • the reagent binds covalently to DNA in the presence of UV light and subsequently binds tightly to avidin.
  • BPsor The biological effectiveness of BPsor was tested by assaying its ability to inhibit lymphocyte proliferation. Freshly prepared peripheral blood lymphocytes were incubated with BPsor and exposed to 3J/cm 2 of near UV light. PHA was then added to the treated cells to stimulate their proliferation, and after three days their growth was assayed by measuring [ 3 H] thymidine incorporation. Proliferation is expressed as the stimulation index, the ratio of [ 3 H] incorporation into cell s with and without PHA addition.
  • BPsor addition to lymphocytes at 1 microgram/ml decreased the stimulation index by more than 99% after irradiation, but had no effect in the dark. See Table I below. TABLE I
  • a biotin-containing psoralen derivative (BPsor) has been synthesized from commercially available reagents in a simple two-step reaction, producing a bifunctional nucleic acid- and avidin-binding reagent.
  • BPsor Like other psoralens, BPsor binds covalently to DNA in a near UV photoreaction, resulting in interstrand crosslinks, and like other biotinylated molecules it binds to avidin, even after it has been incorporated into DNA. The biotinylation does not interfere with its biological activity in lymphocytes; treatment with BPsor at 10 ng/ml plus near UV light inhibits PHA stimulation. BPsor shows a potency comparable to that of its immediate precursor, diaminepsoralen, and higher than that of the commonly used psoralen derivative 8-MOP.
  • BPsor is useful for the following:
  • BPsor Delivery of BPsor to cell s as an avidin-BPsor conj ugate with a readily internal ized mol ecul e, such as transferrin or insulin.
  • a r eversible iminobiotin-Psor shoul d be useful for this purpose , as the drug will bind to avidin wi th a K d of 5 x 10 -7 at extracellular pH, but only 10 -4 in the more acidic endosome, leading to dissociation of most of the psoralen.
  • This internalized compound may then be activated by ultraviolet A energy to kill or functionally impair target cells.
  • the DNA contains a clonable-selectable gene.
  • BPsor may be used to target psoralen to specific cells by attaching it to avidin and a biotinylated cell-specific carrier.
  • the biotinylation of psoralen does not interfere with its biological activity in lymphocytes; treatment with BPsor at 10 ng/ml plus near UV light inhibits cellular proliferation.
  • BPsor exhibits a potency comparable to that of its immediate precursor, diaminepsoralen, and greater than that of the clinically used derivative 8-MOP.

Abstract

Composé de formule (I) dans laquelle Y représente biotine ou iminobiotine, X représente CH2, P représente psoralène ou un dérivé de psoralène, R est un nombre entier égal ou supérieur à 2 et s est un nombre entier égal ou supérieur à 1. Est également décrit un procédé de préparation de psoralène biotinylé ou d'un dérivé de psoralène biotinylé. Sont également décrits des procédés de détection, purification, isolation d'acides nucléiques, des procédés d'administration de psoralène iminobiotinylé à une cellule, ainsi que des procédés de traitement de la leucémie.Compound of formula (I) in which Y represents biotin or iminobiotin, X represents CH2, P represents psoralen or a derivative of psoralen, R is an integer equal to or greater than 2 and s is an integer equal to or greater than 1. Is also describes a process for the preparation of biotinylated psoralen or a biotinylated psoralen derivative. Also disclosed are methods of detection, purification, isolation of nucleic acids, methods of delivering iminobiotinylated psoralen to a cell, as well as methods of treating leukemia.

Description

BIOTINYLATED PSORALENS
This invention was made with government support under grant numbers GM14825 and CA39782 from the U.S. Public Health Service. The U.S. Government has certain rights in the invention.
Background of the Invention
Within this application several publications are referenced by Arabic numerals within parentheses. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entirety are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Psoralen is a linear three ring heterocyclic compound having the structure
It is a bifunctional photoreactive molecule which forms covalent bonds with nucleic acids in the presence of near ultraviolet (UV) light (1). For a review of psoralen photochemistry, see Hearst (2).
Psoralen's ability to react with DNA has given it clinical importance in the treatment of psoriasis and other skin disorders. Additionally, its ability to form interstrand crosslinks in double stranded DNA has made it a useful reagent in the study of nucleic acid structure and function.
Biotin, a growth factor present in very minute amounts in every living cell and occurring mainly bound to proteins or polypeptides, has the structure
Avidin is a glycoprotein containing four essentially identical subunits, each of which is a single polypeptide chain of 128 amino acid residues with a carbohydrate moiety attached at position 17 (3).
Biotin combines with avidin and becomes inactive (4 , 5) . The exceptionally high aff inity of av idin for biotin (Kd = 10-15) has provided the basis for the development of sensitive and specif ic detection systems. Typically, in a multi-step procedure, antigens are recognized by specif ic antibodies, which are then bound to a biotinylated anti-immunoglobul in. This then forms a tight complex with avidin, either conj ugated directly to a signal of some kind, such as a fluorescent dye or enzyme, or in turn bound to a biotinylated label. Alternatively, molecules that are themselves di rectly biotinylated can be recognized di rectly by avidin, omitting the antibody reactions, with their somewhat lower affinities.
In 1985, G.D. Cimino et al. (6) described the synthesis of a psoralen derivative (aminomethyltrioxsalen-AMT) which contains a biotin moiety attached to the 4' position by various undisclosed linker chains. However, the purported methods for synthesizing these compounds were not disclosed. Furthermore, Cimino et al. reported only that preliminary studies of these undisclosed compunds indicated that they could be used to interchalate and crosslink double-stranded nucleic acid and that they can be detected colorimetrically or fluorescently by standard methods based on the avidinbiotin interaction.
Presently, biotinylated psoralens which retain the biological activity of psoralen and the binding specificity of biotin for avidin are not known. Furthermore, methods for synthesizing compounds which retain the biological activity of psoralen and the binding specificity of biotin are not known. A quick, easy, efficient, and safe method for preparing a biotinylated psoralen would provide readily accessible amounts of biotinylated psoralens useful for psoralen modification of cellular components, the visualization of minute amounts of DNA, investigations of the uptake and distribution of psoralen within cells, the delivery of psoralen to specific cells, and the conversion of nucleic acid molecules to ligands for avidin. Summary of the Invention
The present invention provides a compound having the formula
wherein Y is biotin or iminobiotin, X is CH2, P is psoralen or a psoralen derivative, r is an integer equal to or greater than 2 and s is an integer equal to or greater than 1.
The invention also provides a method for preparing a biotinylated psoralen derivative which comprises treating a compound having the structure
L-CH2-P
wherein L is chlorine, bromine, or iodine and P is psoralen or a psoralen derivative linked to L by CH2 at the 4' position of P
with a positively charge multi-aminated linker having two amine groups separated by at least two carbon atoms under suitable conditions so as to allow the formation of a psoralen-linker complex. The psoralen-linker complex is treated with the N-hydroxy succinimide ester of either biotin or iminobiotin under suitable conditions so as to allow the formation of a psoralen-linker-biotin or -iminobiotin complex.
Also provided is a method for delivering to a cell an iminobiotinylated psoralen. This method comprises binding a suitable carrier molecule to biotin so as to form a biotinylated carrier. The biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then reversibly bound to an iminobiotinylated psoralen so as to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex. Cells are treated with a suitable amount of the iminobiotinylated psoralen-avidin-biotinylated carrier complex under suitable conditions so as to permit the iminobiotinylated psoralen-avidin-biotinylated carrier complex to become internalized. The treated cells are incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into a nucleic acid. The incubated cells are then irradiated with near ultraviolet light under suitable conditions to allow the intercalated iminobiotinylated psoralen to covalently bind to the nucleic acid into which it has intercalated, thereby delivering to the cell an iminobiotinylated psoralen.
The invention further provides a method for treating leukemia in a subject. This method comprises binding a suitable carrier molecule to biotin to form a biotinylated carrier. The biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then bound to an iminobiotinylated psoralen to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex. Separetely, plasma and red blood cells are separated from a sample of blood cells and a leukocyte enriched composition is recovered. This leukocyte enriched composition is treated with a suitable amount of the iminobiotinylated psoralen avidin-biotinylated carrier complex, which is permitted to become internalized. The treated leukocyte enriched composition is incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into DNA within the cells. The incubated, treated leukocyte enriched composition is then irradiated with near ultraviolet light so as to allow the intercalated iminobiotinylated psoralen moiety to covalently bind to the DNA into which is has intercalated. A suitable amount of the irradiated leukocyte enriched composition is then administered to the subject, thereby treating the subject for leukemia by providing a toxic dose of psoralen to the leukemic DNA of the subject.
The invention additionally provides a method for detecting the presence of a nucleic acid in a sample. This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid. The sample is then irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which is has intercalated. The biotinylated psoralen which is covalently bound to the nucleic acid is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid. The presence of avidin bound to the biotinylated psoralen, which is also covalenty bound to the nucleic acid, is detected and thereby the presence of the nucleic acid in the sample is detected. Furthermore the amount of a nucleic acid in a sample may be quantitatively determined by contacting the biotinylated psoralen which is covalently bound to the nucleic acid with a known amount of a detectably marked avidin. By determining the amount of avidin bound to the biotinylated psoralen which is also covalently bound to the nucleic acid, the amount of the nucleic acid in the sample is also determined.
The invention also provides a method for purifying or isolating nucleic acid from a sample. This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid. The sample is irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated. The biotinylated psoralen, which is covalently bound to the nucleic acid, is then contacted with an immobilized avidin under suitable condi ti ons so as to allow the avidin moiety to bind to the biotinylated psoralen and form an avidin-biotinylated psoralen-nucleic acid complex. The nucleic acid may then be recovered from the avidin-biotinylated psoralen-nucleic acid complex.
Additionally the invention provides a method for total nucleic acid pattern visualization of a sample. This method comprises electrophoresing the nucleic acid of the sample and immobilizing it to a solid support. The immobilized nucleic acid is contacted with a biotinylated psoralen and the solid support is incubated in the dark for an appropriate amount of time so as to allow the biotinylated psoralen to intercalate into a nucleic acid. Non-intercalated biotinylated psoralen is removed from the solid support and nucleic acid complexes bound to the solid support and intercalated with biotinylated psoralen are irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated. The solid support is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind the biotinylated psoralen, which is covalently bound to the nucleic acid. The presence of avidin bound to the biotinylated psoralen is detected and thereby the total nucleic acid pattern of the sample is visualized.
Furthermore the invention provides a method for visualizing a specific nucleic acid in a sample. This method comprises electrophoresing the nucleic acid of the sample and immobilizing the electrophoresed nucleic acid to a solid support. The immobilized nucleic acid is denatured so as to produced single stranded nucleic acids. Separately, a single stranded nucleic acid clone of the specific nucleic acid to be visualized is contacted with a biotinylated psoralen. The nucleic acid clone is incubated under suitable conditions in the dark so as to allow the formation of biotinylated psoralen-nucleic acid clone complexes, which are then irradiated with near ultraviolet light so as to permit the biotinylated psoralen to covalently bind the nucleic acid clone into which it has intercalated. The immobilized single stranded nucleic acids are contacted with the nucleic acid clone which is covalently bound to the biotinylated psoralen so as to allow the nucleic acid clone and the immobilized single stranded nucleic acids to hybridize. Excess nucleic acid clone which is covalently bound to the biotinylated psoralen is washed from the solid support and the biotinylated psoralen covalently bound to the hybridized nucleic acids is contacted with a detectably marked av idin under suitable condi tions to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the hybridized nucleic acids. The presence of avidin-biotinylated psor alen bound to the hybridized nucleic acid molecules is detected and thereby a specific nucleic acid present in the sample is detected.
Brief Description of the Figures
Fig. 1. Synthesis of biotinylated psoralen.
Fig. 2. DNA crossl inking by BPsor. Linear pBR322 DNA (0.2 micrograms) was near UV irradiated in the presence BPsor. Lane 1: no psoralen, lane 2: 6 ng, lane 3: 15 ng, lane 4: 30 ng, lane 5: 30 ng psoralen, but no irradiation.
Fig. 3. Detection of BPsor modification of DNA by ELISA. Modified DNA on microtiter dishes was incubated sequentially with streptavidin, biotinylated poly alkaline phosphatase, and phosphatase substrate.
Fig. 4. ELISA of BPsor modified DNA. Alkaline phosphatase activity in samples of DNA reacted with BPsor + near UV light ( ● ) or BPsor alone, without irradiation (☐).
Fig. 5. Absorbance spectrum of BPsor. Dashed line = AMT; solid line = BPsor.
Detailed Description of the Invention
The present invention pr ovi des a compound having th e f ormul a
wherein Y is biotin or iminobiotin, X is CH2, P is psoralen or a psoralen derivative, r is an integer equal to or greater than 2 and s is an integer equal to or greater than 1.
in one embodiment of the invention, X is bound to the 4' position of psoralen or a psoralen derivative. The psoralen derivative may be 4, 5', 8 - trimethylpsoralen or 8 - methoxypsoralen.
in a preferred embodiment of the invention, r is the integer 2 and s is the integer 1.
The invention also provides a method for preparing a biotinylated psoralen or a biotinylated psoralen derivative which comprises treating a compound having the structure
L-CH2-P
wherein L is chlorine, bromine, or iodine and P is psoralen or a psoralen derivative linked to L by CH2 at the 4' position of P with a positively charge multi-ami nated linker having two amine groups separated by at least two carbon atoms under suitable conditions so as to allow the formation of a psoralen-linker complex. The psoralen-linker complex is treated with the N-hydroxy succinimide ester of either biotin or iminobiotin under suitable conditions so as to allow the formation of a psoralen-linker-biotin or -iminobiotin complex.
Also provided is a method for delivering to a cell an iminobiotinylated psoralen. This method comprises binding a suitable carrier molecule, i.e. a molecule which is capable of cellular internalization by receptor mediated endocytosis, to biotin so as to form a biotinylated carrier. The biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then reversibly bound to an iminobiotinylated psoralen so as to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex. Cells are treated with a suitable amount of the iminobiotinylated psoralen-avidin-biotinylated carrier complex under suitable conditions so as to permit the iminobiotinylated psoralen-avidin-biotinylated carrier complex to become internalized. The treated cells are incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into a nucleic acid. The incubated cells are then irradiated with near ultraviolet light under suitable conditions to allow the intercalated iminobiotinylated psoralen to covalently bind to the nucleic acid into which it has intercalated, thereby delivering to the cell an iminobiotinylated psoralen. Within this application "suitable carrier molecule" includes, but is not limited to, insulin and transferrin.
The invention further provides a method for treating leukemia in a subject. This method comprises binding a suitable carrier molecule to biotin to form a biotinylated carrier. The biotinylated carrier is bound to avidin so as to form an avidin-biotinylated carrier complex, which is then bound to an iminobiotinylated psoralen to form an iminobiotinylated psoralen-avidin-biotinylated carrier complex.
Separetely, plasma and red blood cells are separated from a sample of blood cells and a leukocyte enriched composition is recovered. This leukocyte enriched composition is treated with a suitable amount of the iminobiotinylated psoralen avidin-biotinylated carrier complex, which is permitted to become internalized. The treated leukocyte enriched composition is incubated in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into DNA within the cells. The incubated, treated leukocyte enriched composition is then irradiated with near ultraviolet light so as to allow the intercalated iminobiotinylated psoralen moiety to covalently bind to the DNA into which is has intercalated. A suitable amount of the irradiated leukocyte enriched composition is then administered to the subject, thereby treating the subject for leukemia by providing a toxic dose of psoralen to the leukemic DNA of the subject.
The invention additionally provides a method for detecting the presence of a nucleic acid in a sample.
This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid. The sample is then irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which is has intercalated. The biotinylated psoralen which is covalently bound to the nucleic acid is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid. The presence of avidin bound to the biotinylated psoralen, which is also covalenty bound to the nucleic acid, is detected and thereby the presence of the nucleic acid in the sample is detected.
The nucleic acid may be DNA or RNA. Furthermore the amount of a nucleic acid in a sample may be quantitatively determined by contacting the biotinylated psoralen which is covalently bound to the nucleic acid with a known amount of a detectably marked avidin. By determining the amount of avidin bound to the biotinylated psoralen which is also covalently bound to the nucleic acid, the amount of the nucleic acid in the sample is also determined.
The invention also provides a method for purifying or isolating nucleic acid from a sample. This method comprises contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid. The sample is irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated. The biotinylated psoralen, which is covalently bound to the nucleic acid, is then contacted with an immobilized avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen and form an avidin-biotinylated psoralen-nucleic acid complex. The nucleic acid may then be recovered from the avidin-biotinylated psoralen-nucleic acid complex.
Additionally the invention provides a method for total nucleic acid pattern visualization of a sample. This method comprises electrophoresing the nucleic acid of the sample and immobilizing it to a solid support. The immobilized nucleic acid is contacted with a biotinylated psoralen and the solid support is incubated in the dark for an appropriate amount of time so as to allow the biotinylated psoralen to intercalate into a nucleic acid. Non-intercalated biotinylated psoralen is removed from the solid support and nucleic acid complexes bound to the solid support and intercalated with biotinylated psoralen are irradiated with near ultraviolet light to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid into which it has intercalated. The solid support is contacted with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind the biotinylated psoralen, which is covalently bound to the nucleic acid. The presence of avidin bound to the biotinylated psoralen is detected and thereby the total nucleic acid pattern of the sample is visualized.
Furthermore the invention provides a method for visualizing a specific nucleic acid in a sample. This method comprises electrophoresing the nucleic acid of the sample and immobilizing the electrophoresed nucleic acid to a solid support. The immobilized nucleic acid is denatured so as to produced single stranded nucleic acids. Separately, a single stranded nucleic acid clone of the specific nucleic acid to be visualized is contacted with a biotinylated psoralen. The nucleic acid clone is incubated under suitable conditions in the dark so as to allow the formation of biotinylated psoralen-nucleic acid clone complexes, which are then irradiated with near ultraviolet light so as to permit the biotinylated psoralen to covalently bind the nucleic acid clone into which it has intercalated. The immobilized single stranded nucleic acids are contacted with the nucleic acid clone which is covalently bound to the biotinylated psoralen so as to allow the nucleic acid clone and the immobilized single stranded nucleic acids to hybridize. Excess nucleic acid clone which is covalently bound to the biotinylated psoralen is washed from the solid support and the biotinylated psoralen covalently bound to the hybridized nucleic acids is contacted with a detectably marked avidin under suitable conditions to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the hybridized nucleic acids. The presence of avidin-biotinylated psoralen bound to the hybridized nucleic acid molecules is detected and thereby a specific nucleic acid present in the sample is detected.
The invention also provides a cross-linked double stranded nucleic acid represented by the structure wherein A is a purine or a pyrimidine, B2 and B3 are purines, B1 and B4 are pyrimdines, W is a biotinylated psoralen cross-linked to B1 and B4 such that the 3, 4 and 4', 5' double bonds of W react with the 5, 6 double bonds of B1 and B4 to form cyclobutane products, Z is H or OH and m and n are integers from 0 to about 100,000.
Also provided is a single stranded nucleic acid represented by the structure
wherein A is a purine or a pyrimidine, B is a pyrimidine, W is a biotinylated psoralen linked to B such that either the 3, 4 or the 4', 5' double bond of W reacts with the 5, 6 double bond of B to form a cyclobutane product, Z is H or OH, and m and n are integers from 0 to 100,000.
The invention further provides a method for detecting in a sample a biotinylated substance. This method comprises contacting a cross-linked double stranded nucleic acid of the present invention with avidin under suitable conditions to allow the avidin to bind to the biotinylated psoralen moiety and form an avidin-biotinylated psoralen-nucleic acid complex. The sample is contacted with the avidin-biotinylated psoralen-nucleic acid complex under suitable conditions to allow the formation of a biotinylated substance-avidin-biotinylated psoralen-nucleic acid complex, the nucleic acid moiety of which is detected, thereby detecting the presence of the biotinylated substances.
The biotinylated substance which is detected may be a biotinylated molecule, cell component, or intact cell.
Furthermore, the nucleic acid moiety may be detected by a colorimetric, chemical, or radioactive technique.
A method for detecting in a sample an avidinylated substance is also provided by the present invention.
This method comprises contacting the sample with a cross-linked double stranded nucleic acid molecule of the present invention under suitable conditions to allow the formation of avidinylated substance-biotinylated psoralen-nucleic acid complexes. The presence of the nucleic acid moiety of the complexes is detected, thereby detecting the presence of the avidinylated substance.
The avidinylated substance may be an avidinylated molecule, cell component, or intact cell. Additionally, the nucleic acid moiety may be detected by a colorimeteric, chemical, or radioactive technique.
Materials and Methods
Synthesis of Biotinylated Psoralen
Diaminepsoralen (DAPS) was prepared from chloromethyl-trimethylpsoralen and sym-dimethylethylene diamine (Aldrich) as described by Welsh (7). Twelve mg of DAPS were dissolved in 0.4 ml dimethylformamide and 15 mg of NHS biotin (Pierce) was added as a solid. The reaction proceeded at room temperature. Reaction progress was followed by thin layer chromatography (TLC) on silica in CH2Cl2: NH3 saturated methanol (15:1). The Rf's of DAPS, NHS biotin, and the reaction product were 0.25, 0 and 0.28 respectively. After one hour the reaction was complete and the solvent was rotoevaporated off, leaving a yellow oil. All steps were carried out under subdued light, and vessels were covered with aluminum foil when possible.
The product was purified by flash chromatography on a 30 x 2.5 cm column of silica gel in the TLC solvent system CH2Cl2: NH3 saturated methanol (15:1) . The reaction mixture did not dissolve directly in the running solvent, so the yellow oil was first taken up in 0.1 ml CH3OH, and then 1.5 ml CH2Cl2 was added to the solution. Fractions of about 10 ml were collected by hand and analyzed by TLC. Fractions 15-22 contained the reaction product, running as a single spot with blue fluorescence at Rf - 0.28. Fractions 17-20 were pooled, dried down, taken up in running solvent as before, and rechromatographed.
The flash column fractions were analyzed by high pressure liquid chromatography (HPLC) on a reverse phase column, in CH3CN: 0.05 M NH4OAc (42.5:57.5) . Aliquots of the fractions were dried down and dissolved in CH3CN. Each fraction ran as a single sharp peak with a retention time of 5.5 minutes. In this system DAPS and NHS biotin have retention times of 6.2 and 4.1 minutes respectively.
[3H] labelled biotinylated psoralen was prepared from diaminepsoralen and [3H] NHS biotin (Amersham), and purified by preparative HPLC. The specific activity was 3.8 x 1011 cpm/mmol.
DNA Crosslinking
Plasmid pBR322 DNA was linearized with Hindlll, and the DNA purified by phenol extraction, followed by ethanol precipitation and resuspension in 10mM Tris HCl, 1mM
EDTA, pH 8.0 (TE) at 0.1 mg/ml. Two micrograms of linear plasmid was mixed with 0 to 10 microliters of
5.7 micromolar biotinylated psoralen (BPsor) in a total volume of 12 microliters. The samples were irradiated with two 400 watt mercury vapor lamps through a solution of 40% cobaltous nitrate (w/w), which transmitted light from 340 to 380 nm (8). The light intensity reaching the sample was approximately 0.1 W/cm2 and irradiation was carried out for 10 minutes.
The samples were then alkali denatured and run on a non-denaturing 1% agarose gel in the Tris acetate-EDTA, as described in (9) .
Detection of DNA modification by ELISA
Calf thymus DNA, at a concentration of 20 micrograms/ml (30 mM base pairs) was combined with 6 uM [3H] BPsor in TE buffer. The sample was irradiated with near UV light, then phenol extracted and ethanol precipitated to remove unbound psoralen. The pellet was resuspended in phosphate buffered saline (PBS). The level of BPsor addition was 0.9%, or 1 psoralen/110 base pairs.
Control DNA samples were prepared by omitting BPsor. Unirradiated controls, prepared by incubating DNA with [3H] BPsor in the dark, followed by phenol extraction and ethanol precipitation, did not incorporate any [3H] BPsor. Manipulations with BPsor were conducted in subdued light, with fluorescent room lights turned off, and samples covered with aluminum foil for storage. Microtiter plates were coated with the reacted DNA by adding samples, diluted into PBS, to the wells and drying the plates overnight at 37°C.
The plates were washed three (3) times with IX PBS-0.5% Tween 20, and 200 microliters of 1% fetal calf serum in PBS-Tween was added to block the wells. After one hour at 37°C the solution was shaken off. 100 microliters of 5 microgram/ml streptavidin (Bethesda Research
Labs - BRL) was added per well, followed by one hour incubation at 37°C. The plates were washed three (3) times with PBS-Tween, and 100 microliters of 1 micrograms/ml biotinylated poly-alkaline phosphatase (BRL) was added, followed by a further incubation of one hour at 37°C. The plates were washed with PBS-Tween, then with 0.01 M diethanolamine, pH 8.6. 100 microliters of alkaline phosphatase substrate (Sigma 104), in 1.0 M diethanolamine, pH 8.6, was added, and the plates were read at 405 nm after incubation at
37°C. Lymphocvte proliferation assay
Psoralen-induced inhibition of lymphocyte stimulation was measured by the method of Scherer, et al. (10) with modifications. Lymphocytes were isolated from 50 ml of whole blood by centrifugation on Ficoll Hypaque. They were washed twice in Roswell Park Memorial Institute (RPMI) medium, then resuspended in PBS and adjusted to 106 cells/ml in PBS.
BPsor, in ethanol, was added to 4 ml of cells to a final concentration of 1 to 1000 ng/ml. The final ethanol concentration was 1%. Negative controls contained no drug, while positive controls contained 10 ng/ml AMT, in ethanol. After 20 minutes for drug uptake, 200 microliters of the cell suspension was added to wells in microtiter plates. Two dishes were prepared, each with 10 wells of each drug concentration. One was wrapped in aluminum foil and the second was irradiated with 3 J/cm2 of near UV light. The microtiter plates were centrituged at 1200 rpm for seven minutes, then quickly inverted to discard the PBS. The lymphocytes in the wells were resuspended in 100 microliters RPMI, then half the wells received 100 microliters RPMI-20% fetal calf serum, while the other half received 100 microliters RPMI-20% fetal calf serum-2% PHA. The dishes were incubated for three days at 37°C.
Lymphocyte proliferation was measured by adding 1 microcurie [3H] thymidine to each well on the third morning. After six hours the cells were collected with an automatic harvester onto filter paper and washed with 5% trichloroacetic acid (TCA) and ethanol. The filters were counted in a scintillation counter and the stimulation index was calculated as the ratio of [3H] incorporation +PHA/ incorporation -PHA.
Results
Synthesis of biotinylated psoralen
The biotinylated psoralen molecule (BPsor) consists of a psoralen moiety, connected to biotin by a positively charged linker. The postive charges confer good water solubility to the relatively insoluble psoralen moiety, and the positive charges aid in binding to negatively charged nucleic acids.
The synthesis scheme is outlined in Figure 1. Chloromethyl trimethylpsoralen was reacted with a diamine linker to form diaminepsoralen. The reaction product was purified and a slight excess of the N-hydroxy succinimide ester of biotin was added. The product of this reaction is BPsor. It was isolated by flash chromatography on silica gel, and the purity was checked by HPLC on a reversed phase column. The UV absorbance spectrum is shown in Figure 5.
DNA crosslinking
Psoralens intercalate into DNA in the dark and form covalent bonds at their 3, 4 and 4', 5' double bonds with pyrimidines upon near UV irradiation. If both ends of psoralen are reacted, the result is an interstrand DNA crosslink. The ability of the BPsor to form DNA crosslinks was tested by reacting linear double strand plasmid DNA with this derivative and near UV light. The DNA was then alkali denatured and loaded onto a nondenaturing agarose gel. Crosslinked DNA immediately renatures in the gel buffer and runs as the double stranded form, while non-crosslinked DNA remains single stranded and runs with greater mobility. Increasing amounts of BPsor resulted in increased levels of crosslinking after UV irradiation, while even the greatest amounts of BPsor produced no crosslinking in the absence of light (Figure 2).
ELISA detection of binding to DNA and avidin
In order to ensure that the linker between the psoralen biotin was long enough to allow access by avidin, the availability of the biotin moiety to avidin binding after the reaction of BPsor with DNA was tested by an enzyme linked immunosorbant assay (ELISA). DNA was reacted with [3H] BPsor plus near UV light and, after the removal of noncovalently bound psoralen by phenol extraction, the modified DNA was bound to microtiter dish wells. After blocking, the samples were incubated first with streptavidin, with has low levels of nonspecific binding to nucleic acids. This step was followed by incubation with biotinylated polyalkaline phosphatase and addition of phosphatase substrate. The steps are outlined in Figure 3.
The measured enzyme activity was proportional to the added BPsor and after a two hour incubation, alkaline phosphatase reaction at levels two times above background were seen in the wells with 2 fmol of bound BPsor, corresponding to 0.15ng (Figure 4). After overnight incubation, 1 fmol could be detected above background. Both BPsor and UV irradiation were required for avidin binding. The control samples, which had been incubated with BPsor but not irradiated, stayed at background levels of alkaline phosphatase activity, as did DNA which had been exposed to light in the absence of BPsor.
These results indicate that both portions of the BPsor are functional. The reagent binds covalently to DNA in the presence of UV light and subsequently binds tightly to avidin.
Inhibition of lymphocyte proliferation
The biological effectiveness of BPsor was tested by assaying its ability to inhibit lymphocyte proliferation. Freshly prepared peripheral blood lymphocytes were incubated with BPsor and exposed to 3J/cm2 of near UV light. PHA was then added to the treated cells to stimulate their proliferation, and after three days their growth was assayed by measuring [3H] thymidine incorporation. Proliferation is expressed as the stimulation index, the ratio of [ 3H] incorporation into cell s with and without PHA addition.
BPsor addition to lymphocytes at 1 microgram/ml decreased the stimulation index by more than 99% after irradiation, but had no effect in the dark. See Table I below. TABLE I
Inhibition of Lymphocyte Proliferation
Rel ative Stimulation Index
Treatment - Light + Light
None 1.00 1.00
10 ng/ml BPsor 0.94 0.16
100 ng/ml BPsor -- 0.01
1000 ng/ml BPsor 1.01 0.01
10 ng/ml AMT 1.02 0.02
Lower levels of BPsor inhibited growth somewhat less, but even at 10 ng/ml there was an 85% decrease in stimulation. This compares favorably with values of 100 ng/ml for 8MOP, the psoralen derivative in clinical use and AMT, the most active psoralen derivative, at 10 ng/ml.
Discussion
A biotin-containing psoralen derivative (BPsor) has been synthesized from commercially available reagents in a simple two-step reaction, producing a bifunctional nucleic acid- and avidin-binding reagent.
Like other psoralens, BPsor binds covalently to DNA in a near UV photoreaction, resulting in interstrand crosslinks, and like other biotinylated molecules it binds to avidin, even after it has been incorporated into DNA. The biotinylation does not interfere with its biological activity in lymphocytes; treatment with BPsor at 10 ng/ml plus near UV light inhibits PHA stimulation. BPsor shows a potency comparable to that of its immediate precursor, diaminepsoralen, and higher than that of the commonly used psoralen derivative 8-MOP.
The inclusion of a biotin group in psoralen enables the detection of psoralen derivatives with the exquisite sensitivity characteristic of the avidin-biotin interaction. Avidin-biotin systems have been developed with fluorescent, heavy metal, radioactive, immunological, and enzymatic labels. These labels allow measurement in a variety of systems, such as ELISA, filter hybridization, and microscopy of cells and tissue slices of isolated cellular components. Accordingly, BPsor is useful for the following:
1) Detection of low levels of psoralen addition to cellular components, e.g. by methods such as the ELISA described herein. 2) Local ization ot BPsor within cells by microscopy, using f luorescent or enzymatic label s .
3) Visual ization of nucleic acids on f ilter s , gel s , o r other suppor ts by photoreaction with BPsor , followed by avidin-biotin reactions .
4) Isolation of psoralen derivatized molecules by aff inity chromatography on resins such as avidin- agarose. This reaction can be made reversibl e by using psoralen derivatized with iminobiotin, which dissociates f rom avidin at l ow pH.
5 ) Delivery of BPsor to cell s as an avidin-BPsor conj ugate with a readily internal ized mol ecul e, such as transferrin or insulin. A r eversible iminobiotin-Psor shoul d be useful for this purpose , as the drug will bind to avidin wi th a Kd of 5 x 10 -7 at extracellular pH, but only 10-4 in the more acidic endosome, leading to dissociation of most of the psoralen. This internalized compound may then be activated by ultraviolet A energy to kill or functionally impair target cells. It is contemplated by the inventors that such a method, used in conjunction with an extracorporeal ultraviolet exposure system such as that described in U.S. Patent No. 4,321,919 would be useful for the treatment of lymphocytic leukemias and immunologic disorders.
6) Purification of nucleic acids that hybridize to a probe by crosslinking, denaturing and capturing by avidin affinity. Such a system is advantageous in that it permits an extra denaturation step. 7) Using DNA molecules to amplify detection of a biotinylated molecule by a DNA based cascade. For example, to amplify an immunoassay, antibody to the antigen to be detected is adsorbed to a microtiter well surface. Following reaction with the antigen specimen, biotinylated antibody against the antigen is complexed. Avidin is then added and further reacted with DNA which has previously been extensively photoderivatized with BPsor. Further amplification is achieved by additional complexing with avidin and a BPsor reacted DNA.
In an extreme version of this method the DNA contains a clonable-selectable gene.
BPsor may be used to target psoralen to specific cells by attaching it to avidin and a biotinylated cell-specific carrier. The biotinylation of psoralen does not interfere with its biological activity in lymphocytes; treatment with BPsor at 10 ng/ml plus near UV light inhibits cellular proliferation. BPsor exhibits a potency comparable to that of its immediate precursor, diaminepsoralen, and greater than that of the clinically used derivative 8-MOP.
References
1. Cole, R.S., Biochem. Biophys. Acta 254: 30-39
(1971) .
2. Hearst, J.E., Ann. Rev. Biophys. Bioeng. 10: 69-86 (1981).
3. DeLange, Huang, J. Biol. Chem. 246: 698 (1971) .
4. Becker, Wilchek, Biochem. Biophys. Acta 264: 165
(1972) .
5. Green, Advan. Protein Chem. 29: 85-133 (1975) .
6. Cimino, G.D., Gramper, H. B., Isaacs, S.T., and Hearst, J.E., Ann. Rev. Biochem 54: 1151-1193 (July 8, 1985).
7. Welsh, Ph.D. thesis, Columbia University (1984) .
8. Isaacs, S.T., et al., Biochemistry 16: 1058-1064 (1977).
9 Saffran, W.A. Goldenberg, M., Cantor, C.R., Proc. Natl. Acad. Sci. USA 79 4594-4598 (1982).
10. Scherer, R., et al., Br. J. Dermatol., Suppl. B 97 : 519-528 (1977).

Claims

Wha t is claimed is :
1 . A compound hav ing the formula
wher ein :
Y is biotin or iminobiotin;
X is CH2;
P is psoralen or a psoralen derivative;
r is an integer equal to or greater than 2; and
s is an integer equal to or greater than 1
2. A compound according to claim 1, wherein Y is biotin.
3. A compound according to claim 1, wherein Y is iminobiotin.
4. A compound according to claim 1, wherein X is bound to the 4' position of psoralen or a psoralen derivative.
5. A compound according to claim 4,wherein P is psoralen.
6. A compound according to claim 4, wherein P is 4, 5', 8 - trimethylpsoralen or 8 - methoxypsoralen.
7. A compound according to claim 1, wherein r is the integer 2 and s is the integer 1.
8. A method for preparing a biotinylated psoralen or a biotinylated psoralen derivative which comprises:
treating a compound having the structure
L-CH2-P
wherein:
L is chlorine, bromine, or iodine; and
P is psoralen or a psoralen derivative Linked to L by CH2 at the 4' position of P
with a positively charged multi-aminated linker having two amine groups separated by at least two carbon atoms under suitable conditions so as to allow the formation of a psoralen - linker complex; and
treating the psoralen - linker complex with the N-hydroxy succinimide ester of either biotin or iminobiotin under suitable conditions so as to allow the formation of a psoralen - linker - biotin or - iminobiotin complex.
9. A method of claim 8, wherein the multi-aminated linker compound is a diamine linker.
10. A method for delivering to a cell an iminobiotinylated psoralen which comprises: binding a suitable carrier molecule to biotin so as to form a biotinylated carrier;
binding the biotinylated carrier to avidin so as to form an avidin - biotinylated carrier complex;
reversibly binding the avidin-biotinylated carrier complex to an iminobiotinylated psoralen so as to form an iminobiotinylated psoralen avidin - biotinylated carrier complex;
treating the cell with a suitable amount of the iminobiotinylated psoralen - avidin biotinylated carrier complex;
permitting the iminobiotinylated psoralen avidin -biotinylated carrier complex to become internalized;
incubating the treated cells in the dark under suitable conditions so as to permit the iminobiotinylated psoralen moiety to dissociate from avidin and intercalate into a nucleic acid; and
irradiating the treated cells with near ultraviolet light under suitable conditions so as to allow the intercalated iminobiotinylated psoralen to covalently bind to the nucleic acid, thereby delivering to a cell an iminobiotinylated psoralen.
11. A method of claim 10, wherein the suitable carrier molecule is insulin or transferrin.
12. A method for treating leukemia in a subject which comprises:
binding a suitable carrier molecule to biotin so as to form a biotinylated carrier;
binding the biotinylated carrier to avidin so as to form an avidin - biotinylated carrier complex;
binding the avidin - biotinylated carrier complex to an iminobiotinylated psoralen so as to form an iminobiotinylated psoralen - avidin - biotinylated carrier complex;
separating plasma and red blood cells from a sample of blood cells and recovering a leukocyte enriched composition;
treating the leukocyte enriched composition with a suitable amount of the iminobiotinylated psoralen - avidin -biotinylated carrier complex;
permitting the iminobiotinylated psoralen avidin - biotinylated carrier complex to become internalized;
incubating the treated leukocyte enriched composition in the dark under suitable conditions so as to permit the immobiotinylated psoralen moiety to dissociate from avidin and intercalate into DNA within the cells;
irradiating the incubated, treated leukocyte enriched composition with near ultraviolet light so as to allow the intercalated iminobiotinylated psoralen moiety to covalently bind the DNA; and
administering an appropriate amount of the irradiated leucokyte enriched composition to the subject, thereby providing a toxic dose of psoralen to the leukemic DNA of the subject.
13. A method of claim 12, wherein the suitable carrier molecule is insulin or transferrin.
14. A method for detecting the presence of a nucleic acid in a sample which comprises:
contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid;
irradiating the sample with near ultraviolet light so as to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid;
contacting the biotinylated psoralen which is covalently bound to the nucleic acid with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid; and
detecting the presence of avidin bound to the biotinylated psoralen which is covalently bound to the nucleic acid, thereby detecting the presence of the nucleic acid in the sample.
15. The method of claim 14, wherein the nucleic acid is DNA.
16. The method of claim 14, wherein the nucleic acid is RNA.
17. A method for quantitatively determining the amount of nucleic acid in a sample which comprises:
contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid;
irradiating the sample with near ultraviolet light so as to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid;
contacting the biotinylated psoralen which is covalently bound to the nucleic acid with a known amount of a detectably marked avidin under suitable conditions so as to permit the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid; and
determining the amount of avidin bound to the biotinylated psoralen which is covalently bound to the nucleic acid, thereby determining the amount of the nucleic acid in the sample.
18. A method for purifying or isolating nucleic acid from a sample which comprises: contacting the sample under suitable conditions in the dark with a biotinylated psoralen so as to allow the biotinylated psoralen to intercalate into a nucleic acid;
irradiating the sample with near ultraviolet light so as to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid;
contacting the biotinylated psoralen which is covalently bound to the nucleic acid with an immobilized avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid and form an avidin - biotinylated psoralen - nucleic acid complex; and
recovering the nucleic acid from the avidin - biotinylated psoralen - nucleic acid complex, thereby purifying or isolating nucleic acid from the sample.
19. A method for total nucleic acid pattern visualization of a sample which comprises:
electrophoresing the nucleic acid of the sample;
immobilizing the nucleic acid to a solid support;
contacting nucleic acid immobilized to the solid support with a biotinylated psoralen; incubating the solid support in the dark for an appropriate amount of time so as to allow the biotinylated psoralen to intercalate into a nucleic acid;
removing non-intercalated biotinylated psoralen from the solid support;
irradiating the nucleic acid complexes bound to the solid support and intercalated with biotinylated psoralen with near ultraviolet light so as to permit the intercalated biotinylated psoralen to covalently bind the nucleic acid;
contacting the solid support with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the nucleic acid; and
detecting the presence of avidin bound to the biotinylated psoralen which is covalently bound to the nucleic acid, thereby visualizing the total nucleic acid pattern of the sample.
20. A method for visualizing a specific nucleic acid in a sample which comprises:
electrophoresing the nucleic acid of the sample;
immobilizing the nucleic acid to a solid support; denaturing the immobilized nucleic acid so as to produce single stranded nucleic acids;
contacting a single stranded nucleic acid clone of the specific nucleic acid to be visualized with a biotinylated psoralen;
incubating the nucleic acid clone under suitable conditions in the dark so as to allow the formation of biotinylated psoralen-nucleic acid clone complexes;
irradiating the biotinylated psoralen - nucleic acid clone complexes with near ultraviolet light so as to permit the biotinylated psoralen to covalently bind the nucleic acid clone;
contacting the immobilized single stranded nucleic acids with the nucleic acid clone covalently bound to the biotinylated psoralen so as to allow the nucleic acid clone and the immobilized single stranded nucleic acids to hybridize;
washing excess nucleic acid clone covalently bound to the biotinylated psoralen from the solid support;
contacting the biotinylated psoralen covalently bound to the hybridized nucleic acids with a detectably marked avidin under suitable conditions so as to allow the avidin moiety to bind to the biotinylated psoralen which is covalently bound to the hybridized nucleic acids; and detecting the presence of avidin - biotinylated psoralen bound to the hybridized nucleic acid molecules, thereby detecting a specific nucleic acid present in the sample.
21. A cross-linked double stranded nucleic acid represented by the structure:
wherein A is a purine or a pyrimidine; B2 and B3 are purines;
B1 and B4 are pyrimidines;
W is a biotinylated psoralen cross-linked to B1 and
B4 such that the 3, 4 and 4', 5' double bonds of W react with the 5, 6 double bonds of B1 and B4 to form cyclobutane products;
Z is H or OH; and m and n are integers from 0 to about 100,000.
22. A single stranded nucleic acid respresentd by the structure:
wherein A is a purine or a pyrimidine; B is a pyrimidine;
W is a biotinylated psoralen linked to B such that either the 3, 4 or the 4', 5' double bond of W reacts with the 5, 6 double bond of B to form a cyclobutane product;
Z is H or OH; and m and n are integers from 0 to about 100,000.
23. A method for detecting in a sample a biotinylated substance which comprises:
contacting a cross-linked double stranded nucleic acid of claim 21 with avidin under suitable conditions so as to allow the avidin to bind to the biotinylated psoralen moiety and form an avidin-biotinylated psoralen-nucleic acid complex;
contacting the sample with the avidin- biotinylated psoralen-nucleic acid complex under suitable conditons so as to allow the formation of a biotinylated substance - avidin- biotinylated psoralen-nucleic acid complex; and
detecting the presence of the nucleic acid moiety of the biotinylated substance - avidin- biotinylated psoralen-nucleic acid complex, thereby detecting the presence of the biotinylated substance.
24. A method of claim 23, wherein the biotinylated substance is a biotinylated molecule, cell component, or intact cell.
25. A method of claim 23 , wherein the nucleic acid moiety is detected by a col orimetric, chemical , or radioactive technique.
26 . A method f or detecting in a sampl e av idinylated substance which comprises :
contacting the sample with a cross-l inked double stranded nuclei c acid molecule of claim 21 unde r suitable conditions so as to allow the formation of avidinylated substance - biotinylated psoralen-nucleic acid compl exes ; and
detecting the presence of the nucleic acid moiety of the av idinylated substance - biotinylated psoralen-nucleic acid complexes , thereby detecting the pr esence of the av idinylated substance .
27. A method of claim 26, wherein the avidinylated substance is an avidinylated molecule, cell component, or intact cell.
28. A method of claim 26, wherein the nucleic acid moiety is detected by a colorimetric, chemical, or radioactive technique.
BIOTINYLATED PSORALENS
Abstract of the Disclos ure
The present invention pr ov ides a compound hav ing the formula
wherein Y is biotin or iminobiotin, X is CH2, P is psoralen or a psoralen derivative, r is an integer equal to or greater than 2 and s is an integer equal to or greater than 1.
The invention also provides a method for preparing a biotinylated psoralen or a biotinylated psoralen derivative.
Further provided are methods for detecting, purifying, and isolating nucleic acids, methods for delivering an iminobiotinylated psoralen to a cell, and methods for treating leukemia.
EP19870903009 1986-04-02 1987-03-30 Biotinylated psoralens Withdrawn EP0262212A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84742286A 1986-04-02 1986-04-02
US847422 1986-04-02

Publications (1)

Publication Number Publication Date
EP0262212A1 true EP0262212A1 (en) 1988-04-06

Family

ID=25300589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870903009 Withdrawn EP0262212A1 (en) 1986-04-02 1987-03-30 Biotinylated psoralens

Country Status (3)

Country Link
EP (1) EP0262212A1 (en)
AU (1) AU7237287A (en)
WO (1) WO1987005805A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK641487A (en) * 1987-12-07 1989-06-08 Gluetech Aps PROCEDURE FOR MODIFYING POLYMER SURFACES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206232A (en) * 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
US4656252A (en) * 1980-01-24 1987-04-07 Giese Roger W Amidobiotin compounds useful in a avidin-biotin multiple layering process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8705805A1 *

Also Published As

Publication number Publication date
WO1987005805A1 (en) 1987-10-08
AU7237287A (en) 1987-10-20

Similar Documents

Publication Publication Date Title
CA1285330C (en) Analyte detection by means of energy transfer
US4921805A (en) Nucleic acid capture method
EP0131830B1 (en) Labelled nucleic acid probes and adducts for their preparation
EP0165313B1 (en) Nucleic acid hybridization assay
JP4074335B2 (en) Chemiluminescent aryl-substituted 1,2-dioxetanes with high electron count
US4868311A (en) Biotinylated psoralens
Koumanov et al. Cell-surface biotinylation of GLUT4 using bis-mannose photolabels
Dubbelman et al. Hematoporphyrin-induced photo-oxidation and photodynamic cross-linking of nucleic acids and their constituents
Bogorad et al. Dipyrrylmethane intermediate in the enzymic synthesis of uroporphyrinogen
US4307189A (en) Method for the quantitative determination of terminal deoxynucleotidyl transferase in biological samples
EP0153763B1 (en) Affinity chromatography matrix with built-in reaction indicator
Lovenberg et al. Assay of serotonin, related metabolites, and enzymes
Williams et al. [68] Benzophenone-ATP: A photoaffinity label for the active site of ATPases
EP0460576B1 (en) Assay for cobalamins
Riceberg et al. Radioimmunoassays of 3, 4, 5-trimethoxyphenethylamine (mescaline) and 2, 5-dimethoxy-4-methylphenyl-isopropylamine (DOM)
EP0262212A1 (en) Biotinylated psoralens
JPH06506056A (en) Peptide binding assay using MHC antigen
US5227311A (en) Intrinsic factor to determine B12
Saffran et al. Preparation and characterization of blotinylated psoralen
EP0155854B1 (en) Non-radioactive biological probes
EP0301899A2 (en) Nucleic acid capture reagent
US4765972A (en) Vinca alkaloid photoactive analogs and their uses
CN112174902A (en) Oxazepam hapten, oxazepam antigen, and preparation methods and applications thereof
Sinha et al. A minimized Fc binding peptide from protein A induces immunocyte proliferation and evokes Th1-type response in mice
CN112063685B (en) Screening method and application of glutathione S-transferase inhibitor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19880105

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAFFRAN, WILMA, A.

Inventor name: WELSH, JOHN, T.

Inventor name: GASPARRO, FRANCIS, P.

Inventor name: CANTOR, CHARLES, R.

Inventor name: EDELSON, RICHARD, L.